Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-10

FDA Approved: ODEFSEY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ODEFSEY, a fixed-dose combination antiretroviral tablet containing emtricitabine, rilpivirine hydrochloride, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)

Snippet

SUPPL AP for ODEFSEY (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE)